FDA approves tirzepatide for obstructive sleep apnea in adults with obesity
What the Zepbound approval covers, what supported it, and what it does not mean.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What happened?
The FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity, alongside a reduced-calorie diet and increased physical activity.
The decision was based on two randomized, double-blind, placebo-controlled studies lasting 52 weeks. The studies evaluated changes in breathing interruptions during sleep and body weight.
Why it matters
- This was the first FDA-approved medication treatment for certain adults with obstructive sleep apnea.
- It is also a useful reminder that approvals attach to an exact product, population, and use—not to a molecule for every possible sleep or weight concern.
What changed for patients or consumers?
- Eligible adults with obesity and moderate-to-severe obstructive sleep apnea gained an FDA-approved medication option to discuss with a licensed clinician.
- The approval did not replace positive airway pressure or other care for everyone. Treatment decisions still depend on clinical evaluation, contraindications, risks, and patient circumstances.
What remains uncertain?
- How outcomes will look across broader real-world populations and over longer periods
- Which individual patients will have a favorable benefit-risk balance
- How medication fits alongside other sleep-apnea treatments for a specific person
Related fact sheets
Source links
- 1FDA approval announcement
Official FDA announcement with indication, study summary, and safety context.
- 2FDA prescribing information: Zepbound
Official product prescribing information from the FDA.
- 3ClinicalTrials.gov: SURMOUNT-OSA
Registered study record for the supporting clinical program.